SCHEMBL2328962

SCHEMBL2328962

CCCC[C@@H](OS(=O)(=O)c1ccc(C)cc1)C(=O)O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 3/20 0.42
PTGES O14684 2/20 0.42
ALOX5 P09917 2/20 0.42
PPARA Q07869 1/20 0.42
CTRC Q99895 1/20 0.42
ALDH1A1 P00352 2/20 0.42
LMNA P02545 1/20 0.42
ALB P02768 1/20 0.42
CYP2C9 P11712 1/20 0.42
TSHR P16473 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
CA2 P00918 2/20 0.40
PLA2G2C Q5R387 1/20 0.40
CA12 O43570 1/20 0.39
CA9 Q16790 1/20 0.39
PLAU P00749 1/20 0.39
HPN P05981 1/20 0.39
CNR2 P34972 1/20 0.39
STAT3 P40763 1/20 0.39
MMP9 P14780 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10809966 0.94 CTRC (0.48) PPARGPTGESALOX5PPARACTRC
SCHEMBL9458215 0.94 CTRC (0.48) PPARGPTGESALOX5PPARACTRC
SCHEMBL10572149 0.91 CA12 (0.44) PPARGPPARAALDH1A1LMNAALB
SCHEMBL2325751 0.91 CA12 (0.44) PPARGPPARAALDH1A1LMNAALB
SCHEMBL10814013 0.87 ALDH1A1 (0.41) PPARGPTGESALOX5PPARAALDH1A1
SCHEMBL7265141 0.85 SMN1; SMN2 (0.43) PPARGPPARAALDH1A1TDP1STAT3
SCHEMBL1990107 0.85 SMN1; SMN2 (0.43) PPARGPPARAALDH1A1TDP1STAT3
SCHEMBL3064836 0.85 SMN1; SMN2 (0.43) PPARGPPARAALDH1A1TDP1STAT3
SCHEMBL13369726 0.84 KMT2A (0.41) PPARGALOX5ALDH1A1LMNACA2
SCHEMBL9674814 0.84 CTRC (0.51) PPARGPTGESALOX5PPARACTRC

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338621-B2 Process for the preparation of 2-oxo-1-pyrrolidine derivatives UCB S.A. (BE) 2012-12-25 US disclosed
EP-1806339-B1 Process for the preparation of 2-oxo-1-pyrrolidine derivatives UCB PHARMA SA (BE) 2011-08-17 EP disclosed
US-20080009638-A1 PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES UCB S.A. (BE) 2008-01-10 US disclosed
EP-1806339-A1 Process for the preparation of 2-oxo-1-pyrrolidine derivatives UCB, S.A. (BE) 2007-07-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080009638-A1 PROCESS FOR THE PREPARATION OF 2-OXO-1-PYRROLIDINE DERIVATIVES CYP2F1, CYP3A5, SULT1E1 PPARG 1888/4885PTGES 264/4885ALOX5 558/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.